A Phase 3 interventional study of Atropine and Placebo Eyedrops in Myopia, sponsored by Jaeb Center for Health Research. Completed at 13 sites in United States. Open to participants aged 5 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-07-31.
Sponsored by Jaeb Center for Health Research · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing atropine in Myopia — 17 open to participants now, 24 under way, 9 of them phase 3. Atropine · Myopia.
Among the 54 studies testing atropine in Myopia, this one is the 21st largest by enrollment, is one of 7 that started in 2018, is one of 13 in phase 3, and was the 9th registered.
1,162 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →17 of the 54 studies testing atropine in Myopia are open now, in 11 countries. Recruiting first, the newest first:
Jaeb Center for Health Research · Sites in United States
Ages 5–11
Ohio State University · Sites in United States
Ages 6–11 · Healthy volunteers
IDB VisionCare SDN BHD · Sites in Malaysia
Ages 5–10
Ocus Innovation Ireland Limited · Sites in Albania, Italy, Poland and 2 more countries
Ages 3–17
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 3–6
By country, each count listing its studies:
Atropine: first FDA approval 1960 (LOMOTIL), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.
This study: 5 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 16 · Phase 4 8
First in 2005; this study’s year is marked. 7 started in 2018.
This study's enrollment of 200 is above the median of 79 across 926 interventional studies indexed under Myopia.
Median enrollment 144 across the 54 interventional studies. Of the 23 that completed or were terminated, 6 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 54 have an industry lead sponsor. The 10 most frequent:
Jaeb Center for Health Research is the lead sponsor of 129 studies on the registry; 16 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
Jaeb Center for Health Research has 3 studies filed under Myopia — fewer than ten, so there is no comparison to draw.
8 of the studies testing atropine in Myopia that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06708156Phase 3Oupushifang Pharmaceutical Technology Co., Ltd.The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression | 2026-12-31 |
| NCT07329777Phase 3IDB VisionCare SDN BHDAtropine in the Treatment of Myopia Study in Malaysia | 2027-09 |
| NCT07164092Phase 3Mansoura UniversityEfficacy of Topical Atropine Eye Drops for Control of Myopia Progression Among Children Attending Mansoura University Ophthalmic Center | 2027-09 |
| NCT06667037Zhongshan Ophthalmic Center, Sun Yat-sen UniversityOrthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control | 2026-12-31 |
| NCT05379855Eye & ENT Hospital of Fudan UniversityA-eyedrops on Ocular Alignment and Binocular Vision | 2027-02-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 54 studies testing atropine in Myopia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study Objectives
The objectives for this randomized trial are:
Synopsis of Study Design The current study is designed as an efficacy study, making effort to maximize adherence to treatment group assignments. After a run-in phase during which all participants are treated with daily artificial tear eyedrops for 2-4 weeks (and glasses are updated if required) to assess their ability to adhere to daily eye drops, participants are randomly assigned to daily atropine or placebo for 24 months, followed by 6 months off treatment.
Study Objectives
The objectives for this randomized trial are:
Synopsis of Study Design The current study is designed as an efficacy study, making effort to maximize adherence to treatment group assignments. After a run-in phase during which all participants are treated with daily artificial tear eyedrops for 2-4 weeks (and glasses are updated if required) to assess their ability to adhere to daily eye drops, participants are randomly assigned to daily atropine or placebo for 24 months, followed by 6 months off treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Refractive error meeting the following by cycloplegic autorefraction:
Exclusion Criteria:
Females who are pregnant, lactating, or intending to become pregnant within the next 30 months.
0.01% atropine eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off atropine eyedrops
Drug: Atropine
Placebo eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off placebo eyedrops
Other: Placebo Eyedrops
Daily 0.01% atropine eyedrops
Also known as: Low-Dose Atropine
Daily placebo eyedrops
Treatment Group Comparison of Change in Spherical Equivalent Refractive Error.
The primary analysis will be a treatment group comparison of change from baseline to 24-months in spherical equivalent refractive error (SER), as measured by a masked examiner using cycloplegic autorefraction (on-treatment comparison). The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis. The treatment group difference (atropine - placebo) and a 95% confidence interval will be calculated based on the model estimates at 24 months.
Time frame: At 24 months
Primary Outcome Measure Stratified by Sex
NIH-required analysis. Primary outcome measure (stratified by sex): The primary analysis will be a treatment group comparison of change from baseline to 24-months in spherical equivalent refractive error (SER), as measured by a masked examiner using cycloplegic autorefraction (on-treatment comparison). The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis. The treatment group difference (atropine - placebo) and a 95% confidence interval will be calculated based on the model estimates at 24 months.
Time frame: at 24 months
Primary Outcome Measure Stratified by Race
NIH-required analysis. Primary outcome measure (stratified by race): The primary analysis will be a treatment group comparison of change from baseline to 24-months in spherical equivalent refractive error (SER), as measured by a masked examiner using cycloplegic autorefraction (on-treatment comparison). The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis. The treatment group difference (atropine - placebo) and a 95% confidence interval will be calculated based on the model estimates at 24 months.
Time frame: by 24 months
Primary Outcome Measure Stratified by Ethnicity
NIH-required analysis. Primary outcome measure (stratified by ethnicity): The primary analysis will be a treatment group comparison of change from baseline to 24-months in spherical equivalent refractive error (SER), as measured by a masked examiner using cycloplegic autorefraction (on-treatment comparison). The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis. The treatment group difference (atropine - placebo) and a 95% confidence interval will be calculated based on the model estimates at 24 months.
Time frame: at 24 months
Primary Outcome: Mean Change in Spherical Equivalent Refractive Error at 24 Months
The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis.
Time frame: 24 months
Treatment Group Comparison of Change From Baseline to 30 Months in Spherical Equivalent
Treatment group comparison of change from baseline to 30 months in spherical equivalent in each eye as measured by a masked examiner using cycloplegic autorefraction (off-treatment comparison). Calculated based on the model estimates at 24 months.
Time frame: At 30 months
| Milestone | Atropine Group | Placebo Group |
|---|---|---|
| Started | 125 | 62 |
| Completed | 118 | 57 |
| Not completed | 7 | 5 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Lost to follow-up | 4 | 3 |
| Withdrew: Moved residence | 2 | 2 |
The primary analysis will be a treatment group comparison of change from baseline to 24-months in spherical equivalent refractive error (SER), as measured by a masked examiner using cycloplegic autorefraction (on-treatment comparison). The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis. The treatment group difference (atropine - placebo) and a 95% confidence interval will be calculated based on the model estimates at 24 months.
| Participants | Atropine Group | Placebo Group |
|---|---|---|
| <=-3.50 Diopters | 0 | 0 |
| >-3.50 to -3.00 Diopters | 1 | 0 |
| >-3.00 to -2.50 Diopters | 1 | 0 |
| >-2.50 to -2.00 Diopters | 5 | 2 |
| >-2.00 to -1.50 Diopters | 8 | 7 |
| >-1.50 to -1.00 Diopters | 19 | 9 |
| >-1.00 to -0.50 Diopters | 37 | 18 |
| >-0.50 to 0.00 Diopters | 46 | 18 |
| >0 Diopters | 2 | 4 |
Treatment group comparison of change from baseline to 30 months in spherical equivalent in each eye as measured by a masked examiner using cycloplegic autorefraction (off-treatment comparison). Calculated based on the model estimates at 24 months.
| Participants | Atropine Group | Placebo Group |
|---|---|---|
| <=-3.50 Diopters | 1 | 0 |
| >-3.50 to -3.00 Diopters | 2 | 1 |
| >-3.00 to -2.50 Diopters | 5 | 0 |
| >-2.50 to -2.00 Diopters | 5 | 3 |
| >-2.00 to -1.50 Diopters | 8 | 6 |
| >-1.50 to -1.00 Diopters | 22 | 11 |
| >-1.00 to -0.50 Diopters | 35 | 20 |
| >-0.50 to 0.00 Diopters | 36 | 13 |
| >0 Diopters | 4 | 3 |
NIH-required analysis. Primary outcome measure (stratified by sex): The primary analysis will be a treatment group comparison of change from baseline to 24-months in spherical equivalent refractive error (SER), as measured by a masked examiner using cycloplegic autorefraction (on-treatment comparison). The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis. The treatment group difference (atropine - placebo) and a 95% confidence interval will be calculated based on the model estimates at 24 months.
| Diopters | Atropine Group | Placebo Group |
|---|---|---|
| Female | -0.74 ± 0.57 | -0.74 ± 0.70 |
| Male | -0.84 ± 0.70 | -0.75 ± 0.44 |
NIH-required analysis. Primary outcome measure (stratified by race): The primary analysis will be a treatment group comparison of change from baseline to 24-months in spherical equivalent refractive error (SER), as measured by a masked examiner using cycloplegic autorefraction (on-treatment comparison). The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis. The treatment group difference (atropine - placebo) and a 95% confidence interval will be calculated based on the model estimates at 24 months.
| Diopter | Atropine Group | Placebo Group |
|---|---|---|
| White | -0.67 ± 0.55 | -0.74 ± 0.52 |
| Black/African American | -0.84 ± 0.63 | -1.07 ± 0.74 |
| Asian | -1.18 ± 0.80 | -0.26 ± 0.51 |
| More than one race | -0.84 ± 0.68 | -0.61 ± 0.58 |
| Unknown/not reported | -0.10 | — |
NIH-required analysis. Primary outcome measure (stratified by ethnicity): The primary analysis will be a treatment group comparison of change from baseline to 24-months in spherical equivalent refractive error (SER), as measured by a masked examiner using cycloplegic autorefraction (on-treatment comparison). The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis. The treatment group difference (atropine - placebo) and a 95% confidence interval will be calculated based on the model estimates at 24 months.
| Diopters | Atropine Group | Placebo Group |
|---|---|---|
| Not Hispanic or Latino | -0.81 ± 0.66 | -0.78 ± 0.62 |
| Hispanic or Latino | -0.63 ± 0.44 | -0.54 ± 0.42 |
The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis.
| diopters | Atropine Group | Placebo Group |
|---|---|---|
| Primary Outcome: Mean Change in Spherical Equivalent Refractive Error at 24 Months | -3.64 ± 1.46 | -3.54 ± 1.08 |
Collected over Adverse event data was collected for the duration of the study, baseline to 30 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atropine Group | 0/125 (0%) | 2/125 (1.6%) | 109/125 (87.2%) |
| Placebo Group | 0/62 (0%) | 0/62 (0%) | 56/62 (90.3%) |
| Event | Atropine Group | Placebo Group |
|---|---|---|
| HospitalizationGeneral disorders | 2/125 | 0/62 |
| Event | Atropine Group | Placebo Group |
|---|---|---|
| Eye IrritiationEye disorders | 90/125 | 51/62 |
| PhotophobiaEye disorders | 32/125 | 17/62 |
| Vision BlurredEye disorders | 17/125 | 10/62 |
| Allergic ConjunctivitisEye disorders | 10/125 | 5/62 |
| Ocular DiscomfortEye disorders | 8/125 | 5/62 |
| Eye PainEye disorders | 9/125 | 0/62 |
| Meibomian gland dysfunctionEye disorders | 3/125 | 3/62 |
| Visual ImpairmentEye disorders | 6/125 | 2/62 |
| BlepharitisEye disorders | 6/125 | 1/62 |
| HordeolumEye disorders | 2/125 | 2/62 |
| Age, Continuous(years) | Atropine Group | Placebo Group | Total |
|---|---|---|---|
| Mean | 10.1 ± 1.8 | 10.1 ± 1.8 | 10.1 ± 1.8 |
| Age, Customized(Participants) | Atropine Group | Placebo Group | Total |
|---|---|---|---|
| 5 to <7 years | 6 | 3 | 9 |
| 7 to <9 years | 28 | 13 | 41 |
| 9 to <11 years | 50 | 20 | 70 |
| 11 to <13 years | 41 | 26 | 67 |
| Sex: Female, Male(Participants) | Atropine Group | Placebo Group | Total |
|---|---|---|---|
| Female | 65 | 36 | 101 |
| Male | 60 | 26 | 86 |
| Race/Ethnicity, Customized(Participants) | Atropine Group | Placebo Group | Total |
|---|---|---|---|
| White (not Hispanic or Latino) | 58 | 28 | 86 |
| White Hispanic or Latino | 21 | 9 | 30 |
| Black | 20 | 14 | 34 |
| East Asian | 16 | 4 | 20 |
| West Asian / South Asian | 4 | 2 | 6 |
| More Than one race | 6 | 5 | 11 |
| Eye Color(Participants) | Atropine Group | Placebo Group | Total |
|---|---|---|---|
| Brown | 82 | 41 | 123 |
| Not Brown | 43 | 21 | 64 |
| Number of Biological Parents with Myopia(Participants) | Atropine Group | Placebo Group | Total |
|---|---|---|---|
| 0 | 16 | 11 | 27 |
| 1 | 51 | 24 | 75 |
| 2 | 52 | 20 | 72 |
| Myopia history unknown for one or both parents | 6 | 7 | 13 |
| Current Refractive Correction (Single-vision Spectacles or Contact Lenses)(Participants) | Atropine Group | Placebo Group | Total |
|---|---|---|---|
| Yes | 125 | 61 | 186 |
| No | 0 | 1 | 1 |
| Distance Visual Acuity in Habitual Refractive Correction (Mean of Both Eyes)(Participants) | Atropine Group | Placebo Group | Total |
|---|---|---|---|
| <-0.2 logMAR | 0 | 1 | 1 |
| -0.2 to < -0.1 logMAR | 18 | 5 | 23 |
| -0.1 to < 0.0 logMAR | 62 | 35 | 97 |
| 0.0 to < 0.1 logMAR | 36 | 16 | 52 |
| 0.1 to < 0.2 logMAR | 9 | 5 | 14 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the PEDIG public website after the completion of each protocol and publication of the primary manuscript.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: After completion of the protocol and publication of the primary manuscript, the data will be made available for the duration of the grant and any future grants.
Access criteria: Users accessing the data must enter an email address.
Ran from Jun 2018 to primary completion in Apr 2022, 46 months.
Results were first posted in May 2023, 1 year after primary completion.
Of 25 phase 3 interventional studies under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 57. This study's 46 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atropine
Jaeb Center for Health Research →